上海谊众药业股份有限公司（以下简称"上海谊众"）发布的2025年业绩快报显示，报告期内，公司实现 营收3.17亿元，同比增长82.72%；实现归母净利润6413.20万元，同比增长819.42%。上海谊众表示，公 司核心产品注射用紫杉醇聚合物胶束于2025年正式纳入《国家医保药品目录》，在市场准入与用药人数 上大幅提高，带动了公司全年营收与利润增长。 "政策红利的持续释放，是行业企业业绩增长的重要助推因素。医保目录动态调整机制显著缩短了新药 从获批到覆盖的周期，近八成创新药能在两年内进入医保，加速了商业化落地。"无锡医库软件科技有 限公司董事长涂宏钢说。 行业整体向好发展，也不断吸引资本目光。开源证券研报显示，2025年全球医疗健康产业投融资额达 638.82亿美元，同比增长10.13%。从国内来看，医疗健康领域一级市场融资回暖更为明显，2025年全年 投融资总额达737.77亿元，同比增长39.05%；中国新药申报IND数量2025年达2175个，同比增长8.8%。 "亮眼成绩单虽令人振奋，但创新药企仍需警惕研发不确定性与市场竞争加剧的挑战，持续修炼内功仍 是企业长久生存与发展之道。"涂宏钢表示，随着商保目 ...

2025年的A股生物医药板块，有的净利润翻30倍一路狂飙，有的却从行业巅峰摔进亏损泥潭，细分赛道 同样有人吃肉有人喝西北风。 政策压顶、市场洗牌、创新突围，多重变量搅局下，生物医药行业的变革早就不是说说而已，而是真刀 真枪的淘汰赛！ 01 盈亏对半开，要么赢要么凉，鲜有中间地带 2025年的生物医药行业彻底告别了"大家一起喝汤"的温柔时代，迎来了"非赢即亏"的残酷格局。 Wind数据显示，截至2月2日，已发布业绩预告的275家医药上市公司中，138家预盈，137家预亏，几乎 平分秋色。 但赚钱的企业是真的赚麻了。 药明康德直接稳坐盈利王宝座，预计归母净利润达191.51亿元，直接甩开同行一大截。三生国健、吉林 敖东、九安医疗、艾力斯紧随其后，预计净利润均突破20亿元，稳居第一梯队。 增幅方面，赛诺医疗成为年度"预增王"，预计2025年归母净利润同比增幅高达2767%至3233%。 而亏损的企业亏得更是触目惊心。 智飞生物直接爆出预亏超百亿，预计亏损106.98亿元至137.26亿元，同比下滑630%至780%，这是这家 疫苗巨头上市以来的首次年度亏损，昔日风光彻底不再。 一边是百亿盈利的狂欢，一边是百亿亏损的 ...

作者：老萝卜头 2025年的A股生物医药板块，有的净利润翻30倍一路狂飙，有的却从行业巅峰摔进亏损泥潭，细分赛道同样有人吃肉有人喝西北风。 政策压顶、市场洗牌、创新突围，多重变量搅局下，生物医药行业的变革早就不是说说而已，而是真刀真枪的淘汰赛！ 01 盈亏对半开，要么赢要么凉，鲜有中间地带 2025年的生物医药行业彻底告别了"大家一起喝汤"的温柔时代，迎来了"非赢即亏"的残酷格局。 Wind数据显示，截至2月2日，已发布业绩预告的275家医药上市公司中，138家预盈，137家预亏，几乎平分秋色。 但赚钱的企业是真的赚麻了。 药明康德直接稳坐盈利王宝座，预计归母净利润达191.51亿元，直接甩开同行一大截。三生国健、吉林敖东、九安医疗、艾力斯紧随其后，预计净利润均突 破20亿元，稳居第一梯队。 增幅方面，赛诺医疗成为年度"预增王"，预计2025年归母净利润同比增幅高达2767%至3233%。 而亏损的企业亏得更是触目惊心。 智飞生物直接爆出预亏超百亿，预计亏损106.98亿元至137.26亿元，同比下滑630%至780%，这是这家疫苗巨头上市以来的首次年度亏损，昔日风光彻底不 再。 一边是百亿盈利的狂欢，一边是 ...

部分公司净利润同比增速表现较为亮眼，如上海谊众药业股份有限公司(以下简称"上海谊众")等3家公 司净利润同比增长超100%。 前海开源基金首席经济学家杨德龙在接受《证券日报》记者采访时表示，业绩表现不仅折射出上市公司 的发展成色，也成为观察实体经济与产业活力的重要窗口。 据记者梳理，上述168家上市公司中，有157家公司实现盈利，占比93.45%，有107家归属母公司股东的 净利润(以下简称"净利润")实现同比增长，占比63.69%。 具体来看，头部企业盈利能力呈现"压舱石"作用，招商银行（600036）股份有限公司(以下简称"招商银 行")净利润为1501.81亿元，暂居第一名。在盈利保持稳健的同时，招商银行分红也受到市场关注。据 招商银行最新披露，该公司2025年半年度A股分红派息以普通股总股本252.20亿股为基数，每股派发现 金红利人民币1.013元(含税)，共计派发现金红利约人民币255.48亿元(含税)，其中，A股总股本为206.29 亿股，派发A股现金红利约人民币208.97亿元(含税)。 此外，包括杭州海康威视（002415）数字技术股份有限公司、上海国际港务(集团)股份有限公司等在内 的12 ...

Core Insights - The company Shanghai Yizhong reported a net profit attributable to shareholders of 64.13 million yuan for the year 2025, representing a year-on-year increase of 819.42%. Total operating revenue reached 317 million yuan, up 82.72% year-on-year. The growth is primarily attributed to the inclusion of the core product, paclitaxel polymer micelles for injection, in the national medical insurance directory in 2025, which has enhanced market access and increased the number of patients using the drug [1]. Financial Performance - The company's Q3 2025 report indicated a dual growth in revenue and net profit, with a year-on-year increase in net profit attributable to shareholders exceeding 7700% [2]. Stock Performance - Over the past seven trading days (from February 6 to February 13, 2026), Shanghai Yizhong's stock exhibited significant volatility. On February 9, the stock surged by 7.63%, closing at 54.00 yuan. On February 11, the trading volume reached 240 million yuan, with financing purchases amounting to 20.38 million yuan and a financing balance of 563 million yuan. As of February 13, the latest closing price was 53.31 yuan, reflecting a cumulative increase of 6.26% over five days, although there was a 20-day decline of 11.64%. The highest turnover rate during this period was 2.95% on February 9, indicating active trading [3]. Recent Events - On February 10, 2026, the national organization for drug procurement opened bids for the first to eighth batches, involving 316 commonly used drugs across 26 treatment areas, including anti-tumor medications, which may indirectly impact the supply and demand dynamics in the pharmaceutical industry. Additionally, Shanghai Yizhong announced a shareholder reduction plan (not exceeding 3% of shares) on January 30, with no new developments disclosed in the past week, warranting attention to future implementation [4].

Group 1 - Chinese government emphasizes the implementation of policies to promote high-quality development and new growth points [2][39] - Local governments are urged to enhance service awareness and improve administrative efficiency to address business concerns [2][39] - The "14th Five-Year Plan" should focus on practical and systematic planning, avoiding overly ambitious projects [2][39] Group 2 - Recent incidents of Chinese enterprise personnel being detained in the US have raised concerns about the impact on business exchanges [3][40] - The Chinese government has expressed strong opposition to the US's actions and called for the cessation of such practices [3][40] Group 3 - The South Korean stock market experienced a significant drop, triggering temporary trading halts [5][42] - The KOSPI index fell by 5.26%, closing at 4949.67 points, after previously reaching a historic high [6][42][7] - The Indonesian stock market also faced turbulence, with the Jakarta Composite Index dropping by 4.88% [8][43] Group 4 - The domestic futures market saw a rare plunge, with 13 commodity futures hitting the limit down due to panic selling [9][44] - The decline was attributed to a combination of factors, including excessive leverage and market structure vulnerabilities [9][44] Group 5 - The National Investment Silver LOF fund announced a significant adjustment in its valuation method for silver futures contracts [10][45] - This adjustment aims to better reflect international market price fluctuations [10][45] Group 6 - The gaming industry reported record revenue per user, with several A-share companies expecting positive performance [17][52] - The humanoid robot industry is accelerating, with institutions actively researching companies with promising earnings [17][52] Group 7 - Shanghai Yizhong reported a net profit increase of 819.42% for 2025, driven by the inclusion of its core product in the national medical insurance directory [19][53] - The company plans to continue investing in R&D for innovative drugs [19][53] Group 8 - XGIMI Technology and Espressif Systems announced share buyback plans, with total amounts not less than 50 million yuan [20][54] - ST Kaiyuan may face delisting risk due to negative net assets projected for 2025 [21][55]

Group 1: Economic Policies and Developments - The central government has approved the "Modern Capital Urban Circle Spatial Coordination Plan (2023-2035)", aiming to optimize the Beijing-Tianjin-Hebei urban system and enhance the functions of the "Four Centers" in Beijing [1] - A joint guideline by ten departments has been released to establish a low-altitude economy standard system by 2027, with over 300 standards expected by 2030 to support the healthy development of the low-altitude economy [2] Group 2: Company Performance and Announcements - Shanghai Yizhong reported a total revenue of 317 million yuan for 2025, a year-on-year increase of 82.72%, and a net profit of 64.13 million yuan, up 819.42% [4] - Lianyun Technology achieved a total revenue of 1.331 billion yuan in 2025, reflecting a growth of 13.42%, with a net profit of 142 million yuan, increasing by 20.36% [4] - Chip导科技 reported a revenue of 394 million yuan for 2025, an 11.52% increase, but a net profit decline of 4.91% to 106 million yuan [4] - Chip导科技 plans to acquire 100% of Jishun Technology and 17.15% of Shunlei Technology for 402.6 million yuan through a combination of convertible bonds and cash [5] - ST Quanwei has received a notice from creditors about a restructuring application due to inability to repay debts, with the court's acceptance of the application being uncertain [6] Group 3: Market Reactions and Trends - The market is expected to see cautious optimism in February, with a focus on consumer sectors benefiting from policy support and seasonal catalysts [8] - The AI industry is anticipated to continue its advancement, with potential performance boosts in the media sector driven by new product cycles and IP commercialization [8]

Core Viewpoint - Shanghai Yizhong reported a significant increase in net profit for 2025, driven by the inclusion of its core product in the national medical insurance directory and increased R&D investments [2]. Group 1: Company Performance - Shanghai Yizhong's total revenue for 2025 reached approximately 317.08 million yuan, a year-on-year increase of 82.72%, with net profit soaring by 819.42% to about 64.13 million yuan [2]. - Chipway Technology achieved a revenue of 394 million yuan in 2025, reflecting an 11.52% increase, while net profit decreased by 4.91% to 10.6 million yuan [5]. Group 2: Share Buybacks - XGIMI Technology plans to repurchase shares with a total fund of no less than 50 million yuan and no more than 100 million yuan, at a price not exceeding 159.51 yuan per share [3]. - Lexin Technology also intends to repurchase shares with a similar financial commitment, with a maximum price of 170.29 yuan per share [3]. Group 3: Risk Warnings - ST Kaiyuan anticipates a potential delisting risk warning due to expected negative net assets for 2025 [4]. Group 4: Important Investments - Aorui Technology's subsidiary plans to invest approximately 145 million yuan in computing power equipment [7]. - ZTE Corporation intends to invest 117 million yuan in a fund focused on new generation information technology and advanced manufacturing [10]. - Dawn Holdings is set to acquire a plastic and engineering plastic compound business in Vietnam for approximately 15.74 million USD [11]. Group 5: New Projects and Developments - Guangdong Electric Power A announced the successful commissioning of its Maoming Bohua Power Plant, with a total investment of 7.48 billion yuan and an expected annual power generation of 8.6 billion kWh [12]. - Ugreen Technology has submitted an application for H-share listing on the Hong Kong Stock Exchange [12].

Company Announcements - Litong Electronics clarifies that its liquid cooling product development is still in the early discussion stage, and it does not have specific plans for product development or production [2] - Changfei Fiber announces that the global fiber optic cable market environment is normal, and new products related to data centers account for a small proportion of total demand [2] - Rundu Co., Ltd. has a Class 1 innovative drug, but the approval for its injection product remains uncertain [3] - Aorui De plans to invest approximately 145 million yuan in purchasing computing power equipment [3] Investment & Contracts - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization cooperation agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. [4] Equity Changes - Hongxiang Co. plans to transfer 100% equity of Nantong Hanlan to Fujian Mingao for a total price of 120 million yuan, which will help resolve historical debt issues [5] Share Buybacks - Lexin Technology plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [6] - XGIMI Technology also plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [7] Business Performance - Chip导科技 reports a revenue of 394 million yuan for 2025, with a net profit of 106 million yuan, reflecting a 4.91% decrease year-on-year [8] - Sainz plans to engage in molybdenum processing and sales, aiming to recover rhenium [9] - Shenghe Resources announces the unilateral termination of its strategic cooperation with ETM, and it will take legal measures to protect its rights [10] - Lianyun Technology reports a net profit growth of 20.36% for 2025, driven by increased demand for storage products [10] - Shanghai Yizhong reports a staggering net profit growth of 819.42% for 2025, attributed to the inclusion of its core product in the national medical insurance directory [11] Other News - Beiyinmei's controlling shareholder's restructuring plan has been approved by the creditors' meeting, which may lead to changes in shareholder equity [12] - Changchun High-tech's subsidiary has received acceptance for a clinical trial application for a new drug [13][14] - Dingxin Communications' vice president has been warned and fined for suspected short-term trading of company stock [15]

Buyback Announcements - GoerTek has repurchased 1.14% of its shares, spending 1.108 billion yuan, with a total of 40.5481 million shares repurchased at prices ranging from 20.35 to 34.09 yuan per share [18] - Midea Group has repurchased 0.35% of its shares, spending 1.998 billion yuan, with a total of 26.9437 million shares repurchased at prices ranging from 69.50 to 80.44 yuan per share [17] - SF Holding has repurchased approximately 48.2887 million A-shares, with a total amount of about 1.899 billion yuan [1] Stock Trading Anomalies - Maoye Commercial has experienced a significant stock price increase, with a cumulative deviation of 20% over two trading days, indicating potential market overheating and high speculation risk [2] - Jinhui Liquor reported a cumulative stock price deviation of over 20% over three trading days, confirming normal production and no undisclosed major information [3] - Yangtze Optical Fiber has noted that the global optical fiber and cable market environment is normal, with new products related to data centers representing a small proportion of total demand [4] Profit Distribution Plans - Ningbo Fuda plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling 101 million yuan, which accounts for 59.85% of the net profit attributable to shareholders for the first three quarters of 2025 [5] Corporate Investments - Southwest Securities has received approval from the China Securities Regulatory Commission to issue bonds totaling up to 14 billion yuan [6] - Guoneng Rixin plans to increase its stake in Sanas Zhihui to 31% through an investment of 17.625 million yuan, enhancing its capabilities in new energy asset operation services [7] Production Updates - Weiyuan Co. has successfully launched a 250,000 tons/year electrolyte solvent project, enhancing its production capacity for various chemical products [8] Financial Performance - Lianyun Technology reported a net profit of 142 million yuan for 2025, a year-on-year increase of 20.36%, driven by growth in storage product demand [12] - Shanghai Yizhong reported a net profit of 64.132 million yuan for 2025, a significant increase of 819.42%, attributed to the inclusion of its core product in the national medical insurance directory [13]